Log in

NASDAQ:AKCAAkcea Therapeutics Stock Price, Forecast & News

$14.13
+0.23 (+1.65 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.72
Now: $14.13
$14.24
50-Day Range
$13.34
MA: $14.73
$16.78
52-Week Range
$8.00
Now: $14.13
$25.66
Volume207,100 shs
Average Volume275,535 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More
Akcea Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$488.54 million
Cash Flow$0.52 per share
Book Value$5.78 per share

Profitability

Net Income$40.77 million

Miscellaneous

Employees248
Market Cap$1.43 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

How has Akcea Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKCA stock has increased by 5.1% and is now trading at $14.13. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics.

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Akcea Therapeutics.

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) released its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.03. The company earned $16.07 million during the quarter, compared to analyst estimates of $34.85 million. Akcea Therapeutics had a negative return on equity of 6.70% and a negative net margin of 8.59%. The company's revenue for the quarter was down 90.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.15 EPS. View Akcea Therapeutics' earnings history.

What price target have analysts set for AKCA?

4 analysts have issued 1-year price objectives for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $41.00. On average, they expect Akcea Therapeutics' stock price to reach $34.67 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price. View analysts' price targets for Akcea Therapeutics.

Has Akcea Therapeutics been receiving favorable news coverage?

Headlines about AKCA stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akcea Therapeutics earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Akcea Therapeutics.

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the following people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $14.13.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.43 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is www.akceatx.com.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.